Krishna Institute of Medical Sciences announced its audited consolidated financial results for the quarter and financial year ended March 31, 2026. The company reported a 28.2% year-on-year increase in total revenue to INR 3,931 Cr for FY26, compared to INR 3,067 Cr in the previous year. Despite the robust top-line growth, profitability declined with PAT falling to INR 242 Cr from INR 415 Cr in FY25. The board approved these results on May 16, 2026.

FY26 Financial Performance

The company achieved an EBITDA of INR 828 Cr, a marginal increase of 1.6% YoY, while the EBITDA margin contracted to 21.1% from 26.6% in FY25. This margin compression reflects the impact of the company's aggressive expansion strategy and the ramp-up phase of newer facilities. For the fourth quarter of FY26, revenue stood at INR 10.7 Bn, compared to INR 7.97 Bn in Q4 FY25. Q4 EBITDA came in at INR 2 Bn versus INR 1.98 Bn in the year-ago period, with the Q4 EBITDA margin contracting to 19.2% from 24.85% YoY. Q4 consolidated net profit was recorded at INR 425 Mn, compared to INR 1.02 Bn in Q4 FY25.

Q4 FY26 Performance Snapshot

The latest quarterly figures reflect continued revenue momentum alongside margin pressure, consistent with the full-year trend.

Operational Highlights

Operational metrics showed strong volume growth during the fiscal year. Inpatient (IP) volume increased by 15.4% to 2,46,297, while Outpatient (OP) volume surged by 25.4% to 23,00,360. Average Revenue Per Occupied Bed (ARPOB) rose by 14.0% to INR 44,644, and Average Revenue Per Patient (ARPP) grew by 11.4% to INR 1,59,575. In Q4 FY26, ARPOB and ARPP grew by 13.7% and 14.0% YoY respectively, indicating improved operational efficiency.

Strategic Expansion and Outlook

The company continues to expand its footprint, currently operating 26 hospitals with over 7,300 beds across Telangana, Andhra Pradesh, Karnataka, Kerala, and Maharashtra. Management highlighted that four new units in Bengaluru, Kerala, and Thane have shown progress. KIMS Hospitals plans to add more than 1,300 beds through upcoming projects, targeting a total bed capacity of 8,600+. The group remains focused on affordable healthcare models and advanced clinical programs.

The Board of Directors of Krishna Institute of Medical Sciences Limited convened a meeting on May 15, 2026, commencing at 2:00 PM and concluding at 5:00 PM, during which it approved a series of key organizational appointments and a board-level re-designation. The disclosures were made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment of Cost Auditors

The board approved the appointment of M/s. Sagar & Associates, Cost Accountants, as the Cost Auditors of the company for the financial year 2026-27. The firm has been engaged to conduct the audit of the cost records of the company for the term April 1, 2026 to March 31, 2027, with the appointment effective May 15, 2026.

M/s. Sagar & Associates is described as a leading firm of Cost & Management Accountants with diversified activities in the Cost and Management Accounting area. The firm comprises qualified Cost Accountants and has undertaken assignments across various industries, serving leading companies with multiple locations and diversified product portfolios. The firm also has significant exposure to ERP systems, including SAP and ORACLE.

Senior Management Personnel Appointments

Based on the recommendation of the Nomination and Remuneration Committee at its meeting held on May 15, 2026, the board identified the following officials as Senior Management Personnel of the company with immediate effect:

Profiles of Newly Appointed Senior Management Personnel

Mr. Sachin Ashok Salvi – Chief Finance Officer

Mr. Salvi is a Chartered Accountant with over 21 years of experience in finance, accounting, financial reporting, and regulatory compliance. He has played a key role in managing IPO processes, including financial restatements and due diligence. His expertise spans IndAS, ICDS, ICDR regulations, GST, direct and indirect taxation, and regulatory liaison with SEBI, RBI, and tax authorities. He began his career with SD Khanolkar & Co., Mumbai, and later served as Finance Controller and CFO at Thyrocare Group, Navi Mumbai.

Mrs. Nagajayanthi J.R – Company Secretary & Compliance Officer

Mrs. Nagajayanthi J.R is a Fellow Member of the Institute of Company Secretaries of India. She holds a B.A. (Honours) in Economics from Delhi University, a Law degree from Osmania University, and has completed both a Master's degree and a Doctorate in Financial Management. She brings over 25 years of experience in the fields of Secretarial practice, Legal affairs, Corporate Finance, and Compliance.

Mr. Bhaskar Reddy R.K – Chief Risk Officer & Chief Internal Audit

Mr. Bhaskar Reddy R.K is a Chartered Accountant with over 12 years of experience in managing internal audits, governance reviews, risk assessments, and control evaluations. He is skilled in identifying process inefficiencies, strengthening internal controls, improving governance frameworks, and delivering actionable recommendations to management for operational and risk optimization. His experience includes 3 years with global consulting firms — Deloitte and BDO — in Risk Advisory and Business Restructuring engagements.

Re-designation of Mr. Adwik Bollineni

The board also approved the re-designation of Mr. Adwik Bollineni from Non-Executive & Non-Independent Director to Executive & Non-Independent Director of the company, effective May 15, 2026. Mr. Bollineni is a governing member of the Aditya Educational Society and has transformed Srikakulam's Great Eastern Medical School (GEMS) into Andhra Pradesh's second most sought-after medical college. Under his leadership, GEMS became the first and only Indian institution accredited by the Royal College of Surgeons of England for surgical excellence, and GEMS earned the 2024 Chief Minister's Award as the best hospital in Andhra Pradesh. Mr. Adwik Bollineni is the son of Dr. B. Bhaskara Rao, CMD, and brother of Dr. Abhinay Bollineni, Director & CEO.

Regulatory Disclosure

All disclosures pertaining to these appointments and re-designation have been made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated 30th January 2026. The relevant information has also been uploaded on the company's website at kimshospitals.com under the Disclosures section.